Nephros

Nephros FCF Growth

The Year-over-Year Free Cash Flow Growth of Nephros (NEPH) as of Nov 3, 2026 is 400.73 %. In the previous year, Year-over-Year Free Cash Flow Growth was -172.74 % — a change of -331.99% (higher).

FCF Growth

400.73 %

YoY

-331.99%

Last updated:

Year-over-Year Free Cash Flow Growth of Nephros is 2025 400.73 % . Year-over-Year Free Cash Flow Growth of Nephros was 2024 -172.74 % . It decreases by -331.99% higher compared to the previous year.

The Nephros FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-3,939.56 USD
Jan 1, 2019
37.70 USD
Jan 1, 2020
-211.88 USD
Jan 1, 2021
79.66 USD
Jan 1, 2022
-132.00 USD
Jan 1, 2023
122.31 USD
Jan 1, 2024
-172.74 USD
Jan 1, 2025
400.73 USD
The Nephros FCF Growth history
YEARFCF GrowthYoY
400.73 %-331.99%
-172.74 %-241.23%
122.31 %-192.66%
-132.00 %-265.72%
79.66 %-137.60%
-211.88 %-661.95%
37.70 %-100.96%
-3,939.56 %-4,213.08%
95.78 %+119.42%
43.65 %-182.94%
-52.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nephros Stock analysis

What does Nephros do? Nephros, Inc. generates revenue through its Water Filtration and Renal Products segments. The Water Filtration segment sells high-performance water purification filters for hospitals, healthcare facilities, dialysis centers, commercial facilities, military, and outdoor recreation markets. The Renal Products segment offers a second-generation hemodiafiltration system for end-stage renal disease patients. Products include ultrafiltration systems used in medical and commercial applications, with subsidiaries Biocon 1, LLC, Aether Water Systems, LLC, and Specialty Renal Products, Inc. supporting sales and development. The company's water filtration products are sold to hospitals, dialysis centers, and commercial facilities, while the hemodiafiltration system targets healthcare providers treating ESRD patients. Subsidiaries handle specialized development and distribution, ensuring market coverage across medical and commercial sectors. Revenue streams are derived from both segments, with products serving healthcare infrastructure and renal treatment needs. Nephros, Inc. focuses on medical device solutions for renal disease and water purification, leveraging its subsidiaries to expand market reach. The Water Filtration segment serves healthcare and commercial clients, while the Renal Products segment addresses ESRD treatment through advanced hemodiafiltration technology, creating a diversified revenue model. Nephros is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nephros stock

Year-over-Year Free Cash Flow Growth of Nephros is 400.73 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Nephros since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Nephros historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Nephros

All Key Metrics — Nephros